Table 3

Adjusted rate ratio of fatal and non-fatal acute myocardial infarction (MI) for inhaled β2 agonist use during the year before the index date according to concurrent cardiovascular disease and β blocker use

Adjusted*
Cases (n=1127)Controls (n=10766)Crude rate ratioRate ratio95% CI
*Adjusted (after age matching) for sex, number of prescriptions for oral corticosteroids, nasal corticosteroids, inhaled corticosteroids, oral β2 agonist, nebulised β2-agonist, and xanthines in the year before the index date, and presence of cardiovascular risk factors (angina, hypertension, congestive heart failure, arrhythmia, hyperlipidaemia, and diabetes) in the year before the index date.
Subjects with no previous cardiac risk factors:
    n2203982
    No use in past year59.157.01.001.00Reference
    Current use24.625.01.000.97 0.70 to 1.36
    New use2.71.91.581.61 0.68 to 3.79
    First time use (%)0.91.00.931.00 0.24 to 4.24
Subjects with previous cardiac risk factors:
    n9076784
    No use in past year57.058.61.001.00Reference
    Current use24.222.21.121.17 0.97 to 1.41
    New use1.81.80.970.99 0.56 to 1.73
        First time use (%)1.01.00.941.03 0.48 to 2.19
Non-users of β blockers:
    n100210051
    No use55.557.21.001.00Reference
    Current use25.323.71.141.20 1.00 to 1.44
    New use2.11.81.251.32 0.80 to 2.17
    First time use (%)1.01.01.031.10 0.52 to 2.34